Jiangao Song

USPTO Granted Patents = 24 (Patent Applications = 8)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 6.8

ph-index = 7

Forward Citations = 202(Granted Patents)

Location History:

Cupertino, CA (US) (2003 - 2009)
Sunnyvale, CA (2014)
Hayward, CA (US) (2013 - 2015)
Sunnyvale, CA (US) (2009 - 2018)

Company Filing History:

10 out of 43

Cymabay Therapeutics, Inc.

Edison Pharmaceuticals, Inc.

patents

4. 1 out of 271

Johnson & Johnson Consumer Companies, Inc.

patents

5. 1 out of 4,442

Eli Lilly and Company

patents

6. 1 out of 9

Galileo Pharmaceuticals, Inc.

patents

Years Active: 2003-2018

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9925189 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2018-03-27),

2. 9737537 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2017-08-22),

3. 9593109 - Bicyclic agonists of GPR131 and uses thereof (2017-03-14),

4. 9150567 - Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts (2015-10-06),

5. 8975258 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2015-03-10),

6. 8921350 - Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2014-12-30),

7. 8912356 - DCC mediated coupling for halofenate manufacture (2014-12-16),

8. 8846675 - N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders (2014-09-30),

9. 8815886 - Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts (2014-08-26),

10. 8703776 - Agonists of GPR131 and uses thereof (2014-04-22),

11. 8598374 - GPR120 receptor agonists and uses thereof (2013-12-03),

12. 8476308 - GPR120 receptor agonists and uses thereof (2013-07-02),

13. 8410127 - Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts (2013-04-02),

14. 8309600 - GPR120 receptor agonists and uses thereof (2012-11-13),

15. 8299117 - GPR120 receptor agonists and uses thereof (2012-10-30),

Title: The Innovative Journey of Jiangao Song

Introduction

Jiangao Song, based in Sunnyvale, California, is a remarkable inventor known for his significant contributions to the field of pharmacology and medical science. With an impressive portfolio of 24 patents, Song focuses on developing innovative treatments for diabetes and metabolic disorders. His work aims to enhance the quality of life for patients dealing with complex health conditions.

Latest Patents

Among Jiangao Song's latest patents are two notable inventions centered around heterocyclic receptor agonists. These compounds and methods are designed for the treatment of Type II diabetes and other diseases related to poor glycemic control. Not only are these compounds revolutionary in their approach, but they are also orally active, providing a more convenient solution for patients.

Career Highlights

Throughout his career, Jiangao Song has contributed his expertise to companies specializing in biotechnology and pharmaceutical development. Notable among these are Cymabay Therapeutics, Inc. and Metabolex, Inc., where he played a crucial role in advancing medical science through innovative research and development.

Collaborations

Song's journey is enriched by collaborations with talented individuals such as Xin Chen and Jingyuan Ma. Working alongside these professionals has allowed him to leverage diverse expertise, ultimately resulting in the creation of impactful medical solutions.

Conclusion

Jiangao Song stands out as a leading figure in the innovation landscape, particularly in the realm of diabetes treatment. His groundbreaking patents reflect a commitment to improving health outcomes through ingenious pharmacological solutions. As research continues, his contributions will undoubtedly pave the way for future advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.